Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Pozen, Inc. (NQ: POZN)
4.960 USD  -0.160 (-3.13%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Pozen, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
POZEN Announces FDA Acceptance of Filing of New Drug Application for PA32540/PA8140 Tablets
May 29, 2013
from Business Wire News Releases
POZEN to Present at the Jefferies 2013 Global Healthcare Conference
May 23, 2013
from Business Wire News Releases
Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers
May 21, 2013
from Business Wire News Releases
POZEN Reports First Quarter 2013 Results
May 08, 2013
from Business Wire News Releases
POZEN Announces May 8th Webcast of First Quarter 2013 Results
April 30, 2013
from Business Wire News Releases
POZEN to Host Analyst and Investor Update Webcast
April 09, 2013
from Marketwired News Releases
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective
April 05, 2013
from Business Wire News Releases
POZEN Submits New Drug Application for PA32540/PA8140
March 27, 2013
from Business Wire News Releases
POZEN Reports European Patent Office Maintains PA/VIMOVO Patent
March 12, 2013
from Business Wire News Releases
POZEN to Present at the 25th Annual ROTH Conference
March 07, 2013
from Business Wire News Releases
POZEN Reports Fourth Quarter & Year End 2012 Results
March 06, 2013
from Business Wire News Releases
POZEN Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results
February 27, 2013
from Business Wire News Releases
Pozen: An Undervalued Investment and Catalyst Trade Opportunity
February 11, 2013
from Marketwired News Releases
POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference
February 08, 2013
from Business Wire News Releases
POZEN to Present at the 24th Annual Piper Jaffray Healthcare Conference
November 19, 2012
from Business Wire News Releases
POZEN Announces Positive Results for the PA8140-102 Bioavailability Study
November 15, 2012
from Business Wire News Releases
POZEN Reports Third Quarter 2012 Financial Results and Positive PA32540 Clinical Updates
November 08, 2012
from Business Wire News Releases
POZEN Presents Positive PA32540 Pivotal Phase 3 Data at the American Heart Association Scientific Sessions 2012
November 06, 2012
from Business Wire News Releases
POZEN Announces November 8th Webcast of Third Quarter 2012 Results and November 6th Presentation of Phase 3 Results for PA32540 at AHA’s Scientific Sessions 2012
October 29, 2012
from Business Wire News Releases
POZEN Patents Upheld in Treximet Patent Litigation Appeal
October 01, 2012
from Business Wire News Releases
POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study (“Co-Rx”)
August 29, 2012
from Business Wire News Releases
POZEN to Present at the 2012 Stifel Nicolaus Healthcare Conference
August 27, 2012
from Business Wire News Releases
POZEN Provides Update on Its PA Program and Results of Its Type A Meeting with the FDA
August 23, 2012
from Business Wire News Releases
POZEN Reports PA32540 / PA8140 Updates and Second Quarter 2012 Financial Results
August 01, 2012
from Business Wire News Releases
POZEN Announces August 1, 2012 Webcast of Second Quarter 2012 Results
July 18, 2012
from Business Wire News Releases
POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis
June 26, 2012
from Business Wire News Releases
POZEN Announces FDA Response to Its Phase 1, PA32540 Bioequivalence Study Analyses
June 20, 2012
from Business Wire News Releases
POZEN to Present at the 2012 Wells Fargo Securities Healthcare Conference
June 07, 2012
from Business Wire News Releases
POZEN to Present at the Jefferies 2012 Global Healthcare Conference
May 22, 2012
from Business Wire News Releases
PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)
May 19, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here